Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.
Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.
Amphastar Pharmaceuticals (NASDAQ: AMPH) reported second quarter 2026 net revenues of $183.9 million, up 5% year over year. GAAP net income was $30.3 million with diluted EPS of $0.67, while adjusted non-GAAP net income was $40.8 million and adjusted diluted EPS $0.91.
Gross profit rose to $93.5 million with gross margin improving to 50.8% from 49.6%. Product trends included a 3% revenue decline for BAQSIMI® to $45.5 million, an 8% decline for Primatene MIST®, a 42% drop in glucagon, and new ipratropium bromide sales of $8.4 million. “Other products” grew 25% to $66.2 million, driven by iron sucrose, teriparatide, albuterol, phytonadione, sodium bicarbonate, and API sales.
Amphastar achieved the first annual BAQSIMI® net sales milestone of $175.0 million, triggering a $100.0 million payment to Eli Lilly due in the third quarter of 2026. Operating expenses increased, with selling, distribution and marketing, and general and administrative each up 30%, and R&D up 10%. Operating cash flow for the first half of 2026 was $99.2 million. The company also highlighted a pipeline including filed ANDA and biosimilar insulin candidates and multiple proprietary and biosimilar products in development.
Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its second quarter 2026 financial results, for the period ended June 30, 2026, after the market closes on Thursday, August 6, 2026. The company will host a conference call at 2:00 p.m. Pacific Time, accessible via toll-free and international dial-in numbers and through a webcast on its investor website, where a replay will be available within 24 hours.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast will be available on the company’s investor relations website for 30 days.
Amphastar develops and sells injectable, inhalation, intranasal, and API products.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q1 2026 net revenue of $171.2M, GAAP net income of $6.4M ($0.14 diluted) and adjusted non-GAAP net income of $19.5M ($0.42 diluted). Gross margin fell to 41.1%. The company launched Ipratropium Bromide HFA, in‑licensed a synthetic corticotropin, and holds multiple ANDA/biosimilar filings and pipeline programs. A conference call is scheduled May 7, 2026 at 2:00 p.m. PT.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Bank of America Health Care Conference on May 13, 2026 at 3:00 pm PT. Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will discuss corporate strategy. The webcast is available at Amphastar's investor website and will remain online for 30 days.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release first quarter 2026 results for the period ended March 31, 2026, after market close on May 7, 2026, and will hold a conference call the same day at 2:00 p.m. PT. The live call and webcast are available on the company's Investors page; a replay will be posted within 24 hours.
Dial-in numbers are toll-free 877-407-0989 or international 201-389-0921. The company develops and sells injectable, inhalation, intranasal, and API products distributed through GPOs, wholesalers, and retailers.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 25th Annual Needham Healthcare Conference on April 14, 2026 at 11:45 am ET. Executives Bill Peters (CFO), Tony Marrs (EVP Regulatory & Clinical) and Dan Dischner (SVP Corporate Communication) will speak.
The presentation will be streamed via webcast and will be available for 30 days after the presentation. Investors can access the webcast through Amphastar's investor website.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q4 2025 net revenues of $183.1M and fiscal 2025 net revenues of $719.9M. GAAP net income was $24.4M in Q4 and $98.1M for the year; GAAP diluted EPS was $0.51 and $2.03, respectively. Adjusted non-GAAP net income was $34.2M for Q4 and $156.6M for the year. BAQSIMI drove double-digit growth, iron sucrose and teriparatide received FDA approvals, R&D and G&A rose due to clinical programs, ERP and a $23.1M legal settlement. Cash flow from operations was $156.1M.
Amphastar (NASDAQ:AMPH) announced FDA approval of its Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation, found bioequivalent and therapeutically equivalent to Atrovent HFA. The FDA confirmed 180 days of generic exclusivity as the first Paragraph IV ANDA filer.
The company plans a commercial launch early in Q2 2026. IQVIA U.S. sales for Atrovent HFA were about $112 million for the 12 months ended December 31, 2025. Amphastar also disclosed multiple ANDA and biosimilar filings and development programs targeting markets worth billions.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release fourth-quarter 2025 results after market close on Thursday, February 26, 2026 and will host a conference call the same day at 2:00 p.m. Pacific Time.
Investors can access the live call by dialing the provided toll-free or international numbers or via the company's Investors page at www.amphastar.com; a webcast replay will be posted within 24 hours.